Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Newly Diagnosed Glioblastoma
NCT04574856Phase 2Active, not recruiting
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Nov 2020
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in glioblastoma (GBM), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: 12-month overall survival rate. Started Nov 2020; status: active, not recruiting.
02
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04574856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04574856.